Document Detail


Tacrolimus in the treatment of idiopathic nephrotic syndrome.
MedLine Citation:
PMID:  17594193     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The immunosuppressant tacrolimus (FK-506) is a calcineurin inhibitor with a widespread use for the prevention of graft rejection in transplantation medicine. Tacrolimus inhibits the activation of an essential transcription factor for the transcription of cytokine genes in T cells leading to a decreased production of cytokines such as IL-2 and IFN-gamma. As T-cell activation plays a crucial role in the pathogenesis of inflammatory glomerular diseases, there is an increasing number of reports on the use of tacrolimus in nephrotic syndrome. In idiopathic nephrotic syndrome, corticosteroid treatment constitutes the first-line therapy to achieve remission. In the case of steroid resistance or steroid dependence, alternative immunosuppressive strategies are needed. Cyclophosphamide and ciclosporin are well-established drugs in this condition. The present article reviews the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome.
Authors:
Timm H Westhoff; Markus van der Giet
Related Documents :
7718973 - Boucher-neuhauser syndrome associated with hypocalciuric hypercalcemia.
18344643 - Nephrotic syndrome due to primary systemic al amyloidosis, successfully treated with va...
18262293 - The impact of metabolic syndrome on left ventricular function: evaluated by using the i...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  16     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-06-27     Completed Date:  2007-07-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1099-110     Citation Subset:  IM    
Affiliation:
Charité--Campus Benjamin Franklin, Centrum 10--Nephrology, Hindenburgdamm 30, Berlin, Germany. timm.westhoff@charite.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Biopsy, Needle
Child, Preschool
Dose-Response Relationship, Drug
Drug Administration Schedule
Drugs, Investigational*
Female
Follow-Up Studies
Graft Rejection / prevention & control
Humans
Immunohistochemistry
Immunosuppressive Agents / adverse effects,  pharmacology,  therapeutic use*
Kidney Function Tests
Kidney Transplantation / adverse effects,  immunology
Male
Maximum Tolerated Dose
Nephrotic Syndrome / diagnosis*,  drug therapy*
Risk Assessment
Severity of Illness Index
Tacrolimus / adverse effects,  pharmacology,  therapeutic use*
Transplantation Immunology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Drugs, Investigational; 0/Immunosuppressive Agents; 109581-93-3/Tacrolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phenserine.
Next Document:  Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.